Discussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes
The IMID Forum
- Published
- February 13, 2026
- Duration
- 20:50
- Summary source
- description
- Last updated
- Jun 21, 2026
Discusses machine-learning.
Summary
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared …
Intelligent report
Sign in to read teasers, or upgrade to Research Pro to commission a new dossier for this episode. Learn more →
Show notes
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.
Themes
- machine-learning